Latest News

Latest News

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

Chinese Biotech Industry Shows No Signs of Slowing

Chinese Biotech Industry Shows No Signs of Slowing

The Chinese biotechnology sector continues to accelerate, signing high-value deals and expanding its global footprint even as the United States prepares new restrictions on collaborations and funding. Despite growing geopolitical tensions, China’s biopharma industry...

read more
Emerging Drug Therapies in the Fight Against Sarcopenia

Emerging Drug Therapies in the Fight Against Sarcopenia

Why Sarcopenia Matters Sarcopenia, the age-related decline in skeletal muscle mass and strength, has become a growing concern in ageing populations. The condition contributes significantly to frailty, falls, fractures, disability and even mortality, placing an...

read more
Navigating Life with Haemophilia with Pfizer

Navigating Life with Haemophilia with Pfizer

Life with haemophilia can be challenging but advances in science are helping people with haemophilia to lead active and fulfilling lives. What is Haemophilia? Haemophilia is a family of rare genetic blood disorders caused by a clotting factor deficiency, which...

read more
Chinese Biotech Industry Shows No Signs of Slowing

Chinese Biotech Industry Shows No Signs of Slowing

The Chinese biotechnology sector continues to accelerate, signing high-value deals and expanding its global footprint even as the United States prepares new restrictions on collaborations and funding. Despite growing geopolitical tensions, China’s biopharma industry...

read more
Emerging Drug Therapies in the Fight Against Sarcopenia

Emerging Drug Therapies in the Fight Against Sarcopenia

Why Sarcopenia Matters Sarcopenia, the age-related decline in skeletal muscle mass and strength, has become a growing concern in ageing populations. The condition contributes significantly to frailty, falls, fractures, disability and even mortality, placing an...

read more
Navigating Life with Haemophilia with Pfizer

Navigating Life with Haemophilia with Pfizer

Life with haemophilia can be challenging but advances in science are helping people with haemophilia to lead active and fulfilling lives. What is Haemophilia? Haemophilia is a family of rare genetic blood disorders caused by a clotting factor deficiency, which...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Hyperfine Banks on $17.5 Million Public Stock Offering

Hyperfine Banks on $17.5 Million Public Stock Offering

Medical imaging company Hyperfine, listed on the Nasdaq as HYPR, has announced the pricing of an underwritten public offering of 14 million shares of its Class A common stock at $1.25 per share, yielding gross proceeds of approximately $17.5 million before...

read more
US Scientists Create Human Embryos from Skin Cells

US Scientists Create Human Embryos from Skin Cells

In a ground breaking advance in reproductive biology, researchers in the United States have for the first time created early-stage human embryos by converting DNA from skin cells into functional eggs and then fertilising them with sperm. Though still at an...

read more

Further News

CE Marking Is Not Enough: Three Layers for Connected Medical Devices

If your device connects to a network and runs AI, CE marking under MDR or IVDR is only the first layer for connected medical devices. Two further EU frameworks, the AI Act and the Cyber Resilience Act, can also apply, each with obligations that go beyond what MDR...

When Months Become Days: AI’s Edge in Patient Engagement

Every therapy that reaches a patient first has to clear a quieter hurdle that rarely makes headlines: finding enough of the right people to test it. That hurdle is where most clinical programs stumble. Roughly 80% of clinical trials fail to meet their enrollment...

What My Stroke Recovery Taught Me About Mobility and Safer Care

After more than three decades in nursing, I have had the privilege of caring for patients during some of the most vulnerable moments of their lives. I have worked alongside extraordinary nurses, therapists, physicians, and support staff who dedicate themselves to...

Tregzi (Orca Bio): Inside the First Regulatory T-Cell Therapy for Blood Cancer

The US Food and Drug Administration has approved Tregzi, a regulatory T-cell therapy developed by Orca Bio. It is the first treatment built from highly purified regulatory T cells to reach the American market. The FDA cleared Tregzi on 30 June 2026. It is designed to...

Workforce Capability Standardization in Medical Affairs

For decades, the pharmaceutical industry has invested heavily in scientific innovation, regulatory rigor, clinical development, manufacturing quality, and commercial excellence. Yet one of the most important links between innovation and patient impact has remained...

Weekly News Roundup | 06 July 2026

Life science news 6 July 2026: the FDA expands the world’s first CRISPR gene therapy to children as young as two, Ipsen commits up to $1.75 billion for a late-stage blood cancer drug, and two first-in-class FDA approvals reshape the cell therapy landscape in a busy...

Atacicept IgA Nephropathy: FDA Decision Due 7 July

Four days from now, the US Food and Drug Administration is due to hand down its atacicept IgA nephropathy decision, ruling on whether the experimental Vera Therapeutics drug becomes the first therapy to target both BAFF and APRIL in adults with the disease. The...

Clinical Trials Roundup | 03 July 2026

Genmab and AbbVie's epcoritamab meets its primary endpoint in a Phase 3 trial for relapsed or refractory diffuse large B-cell lymphoma, the FDA approves Orca Bio's Tregzi as the first regulatory T-cell therapy to reduce chronic graft-versus-host disease in blood...

Why Jeremy Clarkson’s Prostate Cancer Diagnosis Matters More

Last year it was Joe Biden and Barnaby Joyce who made public their diagnoses of prostate cancer. Before them, came other household names battling this condition – from Ben Stiller to Rod Stewart.  This admission, on Jeremy Clarkson’s own TV show for his need of...

FDA Accelerated Approval: How the Fast-Track Pathway Works

FDA accelerated approval is one of the agency's most powerful and most debated regulatory tools. Designed to speed access to treatments for patients with serious or life-threatening conditions, it has delivered transformative therapies to those with no other options....

AI Governance in Biopharma Is Failing the Translation Test

Artificial intelligence is no longer experimental in biopharma. It is operational. Across drug discovery and development, AI systems are being used to identify targets, design molecules, optimize mRNA constructs, and simulate biological interactions that were...

Beyond Animal Models: iPSC Assays Unlock the Human Brain

For decades, neurodegenerative research has relied heavily on animal models. While transgenic mice and rats have yielded fundamental insights into the architecture of the central nervous system, they consistently hit a translational roadblock when applied to human...

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.